Compare PEG & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEG | TEVA |
|---|---|---|
| Founded | 1903 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3B | 39.9B |
| IPO Year | 1994 | N/A |
| Metric | PEG | TEVA |
|---|---|---|
| Price | $78.81 | $34.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $92.79 | $38.63 |
| AVG Volume (30 Days) | 2.4M | ★ 4.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $12,168,000,000.00 | N/A |
| Revenue This Year | $4.89 | N/A |
| Revenue Next Year | $4.16 | $2.97 |
| P/E Ratio | $53.10 | ★ $28.19 |
| Revenue Growth | ★ 18.25 | N/A |
| 52 Week Low | $76.05 | $14.99 |
| 52 Week High | $91.26 | $37.35 |
| Indicator | PEG | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.50 | 53.34 |
| Support Level | $77.27 | $33.61 |
| Resistance Level | $81.50 | $35.37 |
| Average True Range (ATR) | 1.46 | 1.06 |
| MACD | 0.17 | -0.10 |
| Stochastic Oscillator | 61.37 | 73.16 |
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plants and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system under a contract extension through 2030. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.